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Abstract: Abnormalities of chromosome 17 are important molecular genetic events in 
human breast cancers. Several famous oncogenes (HER2, TOP2A and TAU), tumor 
suppressor genes (p53, BRCA1 and HIC-1) or DNA double-strand break repair gene 
(RDM1) are located on chromosome 17. We searched the literature on HER2, TOP2A, 
TAU, RDM1, p53, BRCA1 and HIC-1 on the Pubmed database. The association of genes 
with chromosome 17, biological functions and potential significance are reviewed. In 
breast cancer, the polysomy 17 (three or more) is the predominant numerical aberration. 
HER2 amplification is widely utilized as molecular markers for trastuzumab target 
treatment. Amplified TOP2A, TAU and RDM1 genes are related to a significant response 
to anthracycline-based chemotherapy, taxane or cisplatin, respectively. In contrast, p53, 
BRCA1 and HIC-1 are important tumor suppressor genes related to breast carcinogenesis. 
This review focused on several crucial molecular markers residing on chromosome 17.  
The authors consider the somatic aberrations of chromosome 17 and associated genes in  
breast cancer. 
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In chromosome 17, several important genes are associated with breast cancer, including oncogenic  
genes HER2, TOP2A and TAU, tumor suppressive genes p53, BRCA1, and HIC-1, as well as DNA 
double-strand break repair and recombination gene RDM1 (Figure 1). In addition, abnormalities of 
chromosome 17 are important molecular genetic events in tumorigenesis, especially in breast cancer [1]. 
Both monosomy or polysomy (three or more) of chromosome 17 can be observed in breast cancer. 
Recently, a growing list of studies suggested that several genes residing on chromosome 17 are linked 
to cancer initiation, progression and therapeutic response. A better understanding of the chromosome 
17 abnormalities will help to select patients who may respond well to some therapies. The examination 
of HER2 expression and copy number amplification (17q21.1) is widely utilized for predicting 
therapeutic response for trastuzumab (Herceptin) not only in breast cancer, but also in malignancies of 
the gastrointestinal tract [2–5].  
Figure 1. Schematic diagram of chromosome 17 and several important molecular markers 
for breast cancer. Gene names are listed on the right side and resided regions are listed on 
the left side. 




The HER2 gene is located on 17q21.1, which encodes the human epidermal growth factor receptor 
2 oncogene, a transmembrane tyrosine kinase receptor. Currently, a series of HER2-targeting agents 
are developed, including trastuzumab, pertuzumab, ertumaxomab and lapatinib. HER2 gene 
amplification or protein overexpression is encountered in approximately 25% of newly diagnosed 
breast cancers. Although the incidence and significance of HER2 amplification in lobular carcinoma 
are lower than that in ductal carcinoma, the HER2 amplification is still a significant adverse prognostic 
factor in lobular breast cancer [6]. One report proposed that tumor-initiating cells (side population 
fraction by cytometry, SP) of breast cancer disclosed significant HER2 expression. The SP fraction 
was decreased by HER2 inhibitors, strengthening the contribution of targeting HER2 to SP phenotype. 
The finding indicates an important role of HER2 in regulating the tumor-initiating cells in breast 
cancer [7]. A meta-analysis for cohort randomized trials on women with HER2-positive early breast 
cancer disclosed that trastuzumab-based adjuvant chemotherapy derived benefit in disease-free 
survival, overall survival and recurrence to adjuvant chemotherapy, but did worse in recurrence on the 
central nervous system compared to the controls [8]. 
Fluorescence in situ hybridization (FISH) is often used for detecting chromosome 17 or HER2 gene 
aberrations. Dual-color FISH is a method for combining analysis of chromosome ploidy and gene copy 
numbers by centromeric 17 and target gene probes. PathVision dual-color FISH Kit is often used for 
detecting chromosome 17 and copy number of HER2 target gene simultaneously, whereas, HercepTest 
Kit is used for detecting HER2 protein (ERBB2) immunohistochemically. Amplification of the HER2 
gene is present in about 25% of breast cancer and leads to an overexpression of the protein that made it 
possible to develop a targeted therapy by the monoclonal antibody trastuzumab. However, the 
suitability of target therapy depends on the stringent assessment of the gene status in tumors. Only 
patients whose tumor shows a high expression of the HER2 protein or an amplification of the gene are 
eligible for target therapy. The candidate gene is considered as amplification when showing more than 
six HER2 copies per nucleus, or with a ratio of HER2 to centromere 17 greater than 2.2. Clusters of 
signals are characteristic of the HER2 amplifications [9].  
The HER2 amplification and over-expression have been related to negative responses to 
conventional chemotherapy and poor prognosis but better overall survival rate for trastuzumab in 
breast cancer [10,11]. The American Society of Clinical Oncology and the College of American 
Pathologists (ASCO/CAP) proposed that HER2 negative means that a tumor with a staining score of  
0 or 1+, or with a ratio of HER2 gene to chromosome 17 less than 1.8, or with four or less HER2 copy 
numbers per cell. The HER2 positivity is defined as a tumor with an immunostaining score of 3+ 
(uniform, intense membrane staining of >30% of invasive tumor cells), or with a ratio of HER2 gene 
to chromosome 17 greater than 2.2, or with six or greater HER2 copy numbers per cell. A tumor with 
an immunostaining score of 2+ should be further tested by FISH. HER2 borderline means that tumor 
samples with a ratio of HER2 gene to chromosome 17 of 1.8 to 2.2, or with greater than four to less 
than six HER2 copy numbers per cell [9,12,13]. Because HER2 and TOP2A are harbored nearby on 
chromosome 17q21-q22, a high concordance of the HER2 and TOP2A gene co-amplification was 
indicated in breast cancer [14]. The FISH method or chromogenic in situ hybridization (CISH) method 
can be taken for HER2 amplification detection. In breast cancer, aneusomy of chromosome 17, either Int. J. Mol. Sci. 2011, 12 5675 
 
 
monosomy (single copy per cell) or polysomy (≥3 copies per cell) is frequently observed by FISH. 
However, the biological significance of aneusomy of chromosome 17 remained controversial [15–19]. 
3. TOP2A 
DNA topoisomerase II alpha (TOP2A) is a novel marker of cell-cycle turnover. Both of TOP2A 
and HER2 gene are located on chromosome 17q21-q22. TOP2A gene is more than 700 kb telomeric to 
HER2 and plays a key role in DNA replication. TOP2A is a major target of anthracycline activity [20]. 
In breast cancer, TOP2A expression has been linked to cell proliferation and HER2 protein 
overexpression. O’Malley et al. found that in patients whose tumors showed TOP2A alterations (either 
amplifications or deletions), treatment with cyclophosphamide, epirubicin, and 5-fluorouracil (CEF) 
was statistically significantly superior to treatment with cyclophosphamide, methotrexate, and   
5-fluorouracil (CMF) in terms of  recurrence-free survival and overall survival. The TOP2A gene 
alterations revealed an increase in responsiveness to anthracycline-containing chemotherapy regimens 
relative to non-anthracycline regimens [21]. Since the gene locus of TOP2A is closely near to HER2 
gene, the amplification of TOP2A is a frequently accompanied by HER2 gene amplification. TOP2A 
amplification in the absence of HER2 amplification may be associated with lower histological grade 
and ER positivity. Orlando et al. assessed the 23 patients with T2-T4 ER absent and HER2 
overexpression breast cancers treated with anthracycline-based chemotherapy. TOP2A was amplified 
in five (22%) of the tumors. In all patients with TOP2A amplification, HER2 gene amplification was 
also detected. The pathological complete remission was reported in three of five amplified tumors 
(60%), compared to that in two of 13 tumors without TOP2A amplification (15%). They proposed that 
in endocrine unresponsive/HER2 overexpression cases, TOP2A amplification or the polysomy of 
chromosome 17 are related to a significantly high remission after anthracycline-based chemotherapy [22]. 
TOP2A is taken as a molecular target of anthracycline drug and is potentially useful as a predictive 
marker of response to anthracycline therapy [23]. 
4. TAU 
TAU is a microtubule-associated protein (MAPs) and located on chromosome 17q21.1.   
Tubulin-targeting agents affect the microtubule function to disrupt cell shape, microvesicle 
transportation and spindle formation. The agents include taxanes, paclitaxel, docetaxel and 
epothilones, which interfere with the spindle microtubule dynamics and cause cell cycle arrest. These 
agents are widely used in the treatment of breast cancer with benefits of overall survival and disease-free 
survival. Detection of TAU expression may help doctors to identify the patients who likely to benefit 
from taxane treatment. The low expression of TAU correlates with sensitivity to paclitaxel in vitro. 
TAU promotes microtubule assembly and stabilizes microtubules, and it is possible that TAU competes 
with taxanes for microtubule binding [24,25]. Researches demonstrated that high TAU mRNA 
expression in ER-positive breast cancer revealed an endocrine-sensitive but chemotherapy-resistant. In 
contrast, low TAU expression in ER-positive cancers revealed a poor prognosis with tamoxifen alone, 
but may benefit from taxane-containing chemotherapy [26]. In addition, Tanaka et al. studied the 
correlation of TAU expression and efficacy of paclitaxel treatment in metastatic breast cancer. They 
found that 57% of breast cancer tissues disclosed TAU expression. A significant difference was Int. J. Mol. Sci. 2011, 12 5676 
 
 
identified between paclitaxel effectiveness and TAU expression. Nine (60%) of 15 cases with   
TAU-negative expression showed favorable response to paclitaxel administration compared with three 
(15%) of 20 cases with TAU-positive expression [27]. 
5. RDM1 
The RDM1 (RAD52 Motif 1) gene locates on 17q11.2, which encodes a protein RAD52 involved in 
DNA double-strand break repair and recombination event. As we know, chemical mutagens and 
ultraviolet lesions can lead to mutational loss of factors important for cell growth and viability. These 
DNA damages need to be repaired. A numbers of genes are involved into DNA repair, including 
excision repair, postreplication repair and recombinational/double-strand break repair. The repair of 
double-strand break is mediated extensively by RDA52-dependent recombination [28]. Hamimes et al. 
found that disruption of RDM1 in the chicken B cell line DT40 led to a more than threefold increase in 
sensitivity to cisplatin. They also found that human RDM1 transcripts are abundant in testis, suggesting a 
possible role during spermatogenesis and maintaining stemness of cells [29,30]. Messaoudi et al. 
studied the subcellular distribution of human RDM1 protein isoforms and proposed that RDM1 null 
chicken DT40 cells displayed an increased sensitivity to heat shock, compared to wild-type cells, 
suggesting a function for RDM1 in the heat-shock response [31]. The deficiency of DNA repair and 
recombination mechanisms led to a hypersensitivity to cisplatin, mitomycin C and bleomycin [32,33]. 
Because either bleomycin (directly) or cisplatin (DNA adduct formation) involves in the DNA   
double-strands break, probing the RDM1 gene aberration may provide a valuable information for 
action of these anticancer agents [34]. However, all the findings come from the experiments in vitro; 
the clinical significance of RDM1 assay needs to be clarified in future.  
6. BRCA1 
The breast cancer susceptibility gene BRCA1 is located on chromosome 17q12-21. BRCA1 
encodes a tumor suppressor protein that acts as a negative regulator of tumor growth and is involved in 
DNA-damage repair. Germline mutation of BRCA1 increases the risk of developing breast cancer. 
Genetic factors contribute to about 5% of all breast cancer cases. In addition, the effect of BRCA1 
mutation moderately increased the risk of ovarian cancer [35]. Rhiem et al. analyzed 105 sporadic 
breast carcinomas and indicated that high frequencies of loss of heterozygosity (LOH) of BRCA1 is 
more observed in estrogen receptor-negative carcinomas than estrogen receptor-positive carcinomas  
(39%:12%; p = 0.003) [36]. Tassone et al. constructed BRCA1-defective or BRCA1-reconstituted 
human breast cancer xenografts models and found that CDDP induced almost complete growth 
inhibition of BRCA1-defective xenograft tumor growth, while BRCA1-reconstituted xenograft tumor 
were only partially inhibited. They proposed that BRCA1-defective xenograft tumor express a high 
sensitivity to platinum-derived chemotherapy [37]. Liu et al. successively induced mammary tumors 
with features of human BRCA1-mutated basal-like breast cancer with somatic loss of BRCA1 and p53 
in mice. Somatic loss of both BRCA1 and p53 resulted in the rapid and efficient formation of highly 
proliferative, poorly differentiated, estrogen receptor-negative mammary carcinomas, reminiscent of 
human basal-like breast cancer [38]. However, somatic BRCA1 mutations are rarely found in sporadic 
breast tumours. BRCA1 methylation has been shown to occur in sporadic breast tumours and to be Int. J. Mol. Sci. 2011, 12 5677 
 
 
associated with reduced gene expression. Thus, epigenetic silencing and deletion of the BRCA1 gene 
might serve as Knudson's two 'hits' in sporadic breast tumorigenesis [39–41].  
7. P53 
The tumor suppressor gene p53 is located on 17p13.1. Wild-type p53 is a checkpoint gene critical 
to control cell growth and to maintain genomic stability. P53 tumor suppressor plays a pivotal role in 
the coordination of the repair process or in the induction of apoptosis. P53 somatic alteration is 
described in approximately 50% of human cancers [42]. Activation of p53 may have potential value as 
cancer therapeutic strategy. Wild-type p53 gene encodes a phosphoprotein, which barely detectable in 
the nucleus of normal cells (with a short half-life of 20 min). Upon cellular stress, particularly that 
induced by DNA damage, p53 can arrest cell cycle progression, thus allowing the DNA to be repaired; 
or leading to apoptosis. In cancer cells bearing a mutant p53, this protein is no longer able to control 
cell proliferation, resulting in inefficient DNA repair and genetic instability. The point missense 
mutation of p53 is the most common change in human cancers, including colon cancer, stomach 
cancer, breast cancer and esophagus cancer. The mutant p53 protein is detectable protein accumulated 
in the nucleus of neoplastic cells (with a longer half-life of several hours). Therefore, positive p53 
immunostaining represents the abnormal p53 gene. During the past few years, the dramatic progress in 
the molecular biology of p53 has raised the exciting prospect for cancer management. MDM2 (also 
named Mdm2 p53 binding protein homolog) can inactivate the p53 via binding to the transactivation 
domain of p53. Overexpression of this gene can result in excessive inactivation of p53 tumor suppressor 
protein. MDM2 has E3 ubiquitin ligase activity, which target p53 for proteosomal degradation. 
Modulting p53 activity with MDM2 inhibitor is a promising approach for treating cancer [43]. A 
small-molecule MDM2 antagonist, nutlin-3 has been developed. Cancer cells with MDM2 gene 
amplification are most sensitive to nutlin-3 in vitro and in vivo. The patients with wild-type p53 tumors 
may benefit from antagonists of the p53-MDM2 interaction [44]. 
8. HIC-1 
Hypermethylated in cancer 1 (HIC-1, also named ZBTB29 or ZNF901) is a candidate tumor 
suppressor gene which is located at 17p13.3, a more distal region of p53 on chromosome 17p, which 
frequently undergoes allelic loss in breast and other human cancers. The human HIC1 gene is 
composed of two exons [45]. HIC-1 is ubiquitously expressed in normal tissues, but low-expressed in 
different tumor cells, including hepatocellular carcinoma, colorectal carcinoma, breast cancer and 
gastric cancer [46–54]. In breast cancer, the loss of heterozygosity at 17p13 combined with p53 gene 
mutation was related to survivin overexpression, a member of the inhibitor-of-apoptosis (IAP)   
family [55]. The DNA hypermethylation of HIC-1 was found in several kinds of tumor [56]. The HIC-1 
protein expression has been linked to better outcomes in breast cancers. Although the molecular 
mechanism underlying HIC1-mediated transcriptional and growth suppression is currently unclear, 
some researchers proposed that HIC-1 targets E2F-responsive genes responsible for transcriptional 
regulation and growth suppression in cancer [57]. Recently, Zhang et al. found that HIC-1 can repress 
the ephrin-A1 transcription, which implicated in the pathogenesis of epithelial cancers. Restoration of 
HIC-1 in breast cancer cells led to a growth arrest in vivo [58]. One report demonstrated that HIC-1 Int. J. Mol. Sci. 2011, 12 5678 
 
 
regulates breast cancer cell responses to endocrine therapies [59]. The expression of HIC-1 is linked to 
p53 status. For instance, MCF-7, a breast cancer cell line with wild type p53 expressed HIC-1, but the 
MDAMB231 breast cancer cell line with mutant p53 did not express HIC-1, suggesting synergistic 
events of loss of HIC-1 expression and p53 mutation in breast cancer. The HIC-1 expression can be 
restored by demethylating drug 5-aza-2'-deoxycytidine in MDAMB231 cells. Therefore, restoration of 
HIC-1 function by demethylation may offer a therapeutic avenue in breast cancer [60]. 
9. Conclusion 
We summarized the important molecular markers resided on chromosome 17 and their biological 
significance (Table 1). We also introduced the examining and evaluating methods for chromosome 17 
and associated molecular markers. This review strengthened the clinical significance of monitoring the 
aberration of molecular markers on chromosome 17 in breast cancer. 
Table 1. Molecular markers and their functions on chromosome 17. 
Gene ID  Name  Location  Functions 
2064  ERBB2/HER2  17q21.1  Epidermal growth factor (EGF) receptor family of receptor 
tyrosine kinases. Amplification and/or overexpression have 
been reported in numerous cancers. 
7153  TOP2A  17q21-q22  DNA topoisomerase, controls and alters the topologic states of 
DNA during transcription. It is associated with the 
development of drug resistance. 
201299  RDM1  17q11.2  RAD52 protein encoded by RDM1 is involved in DNA 
double-strand break repair and recombination event. 
Disruption of the RDM1 gene resulted in an increased 
sensitivity to the anti-cancer drug cisplatin. 
7157  P53  17p13.1  P53 responds to diverse cellular stresses to regulate target 
genes that induce cell cycle arrest, apoptosis, senescence, 
DNA repair. It is accumulated in a variety of transformed cells.  
672  BRCA1  17q21  BRCA1 plays a role in maintaining genomic stability. It acts 
as a tumor suppressor. BRCA1 combines with other tumor 
suppressors, to form a BRCA1-associated genome surveillance 
complex (BASC). Mutations in this gene are responsible for 
approximately 40% of inherited breast cancers and more than 
80% of inherited breast and ovarian cancers. 
3090  HIC-1  17p13.3  Hypermethylated in cancer 1, a candidate tumor suppressor 
gene which undergoes allelic loss in breast and other human 
cancers. The human HIC-1 gene is a target gene of p53.  
4137  TAU  17q21.1  Microtubule-associated protein TAU (MAPT), functions to 
keep cell shape, microvesicle transportation and spindle 
formation. Interfering spindle microtubule dynamics will 
cause cell cycle arrest and apoptosis. TAU detection helps to 
identify those patients who are most likely to benefit from 
taxane treatment and resistant to paclitaxel treatment. Int. J. Mol. Sci. 2011, 12 5679 
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